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OBJECTIVE—To assess the effectiveness of structured blood glucose testing in poorly con-
trolled, noninsulin-treated type 2 diabetes.
RESEARCH DESIGN AND METHODS—This 12-month, prospective, cluster-
randomized, multicenter study recruited 483 poorly controlled (A1C $7.5%), insulin-naïve
type 2 diabetic subjects from 34 primary care practices in the U.S. Practices were randomized
toanactivecontrolgroup(ACG)withenhancedusualcareorastructuredtestinggroup(STG)
with enhanced usual care and at least quarterly use of structured self-monitoring of blood
glucose (SMBG). STG patients and physicians were trained to use a paper tool to collect/interpret
7-pointglucoseproﬁlesover3consecutivedays.The primaryend point wasA1C levelmeasuredat
12 months.
RESULTS—The 12-month intent-to-treat analysis (ACG, n = 227; STG, n = 256) showed
signiﬁcantly greater reductions in mean (SE) A1C in the STG compared with the ACG:
21.2% (0.09) vs. 20.9% (0.10); D = 20.3%; P = 0.04. Per protocol analysis (ACG, n = 161;
STG, n = 130) showed even greater mean (SE) A1C reductions in the STG compared with the
ACG: 21.3% (0.11) vs. 20.8% (0.11); D = 20.5%; P , 0.003. Signiﬁcantly more STG patients
received a treatment change recommendation at the month 1 visit compared with ACG patients,
regardless of the patient’s initial baseline A1C level: 179 (75.5%) vs. 61 (28.0%); ,0.0001. Both
STG and ACG patients displayed signiﬁcant (P , 0.0001) improvements in general well-being
(GWB).
CONCLUSIONS—AppropriateuseofstructuredSMBGsigniﬁcantlyimprovesglycemiccon-
trol and facilitates more timely/aggressive treatment changes in noninsulin-treated type 2 di-
abetes without decreasing GWB.
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S
elf-monitoring of blood glucose
(SMBG) is widely recognized as a
corecomponentofeffectivediabetic
self-management (1–3). Although most
evidence indicatesthat SMBGcontributes
to good glycemic control among type 1
(4,5) and type 2 diabetic (6,7) patients,
it remains uncertain whether SMBG use
is efﬁcacious in insulin-naïve type 2 dia-
betic patients. Current evidence in this
latter population is mixed, with some
studies pointing to signiﬁcant glycemic
beneﬁts resulting from SMBG use (8–
10), while others have shown no signiﬁ-
cant beneﬁts (11–13). Given the growing
cost of current type 2 diabetic care, it is
important to determine whether re-
sources devoted to SMBG in the insulin-
naïve population are justiﬁed and are
effectively applied.
Inconsistent ﬁndings seen in studies
of insulin-naïve type 2 diabetic patients
may be due, in part, to differences in
key design issues, such as subject selec-
tion criteria (e.g., whether or not patients
hadpoorglycemiccontrolatstudyentry),
critical content differences in the actual
SMBG intervention (e.g., whether physi-
cians were privy to patient SMBG data),
ﬁdelity of treatment delivery (e.g., the
same physicians cared for patients from
multiple study groups), and/or interven-
tionadherence(e.g.,whetherpatientsactu-
allycompletedtheSMBG studyprotocolas
directed).Areviewoftheseissueswaspub-
lished previously (14). We developed a
comprehensive, structured SMBG inter-
vention package that addresses these de-
sign issues and encourages patients and
physicians to work collaboratively to col-
lect, interpret, and appropriately use
structured SMBG data. Our study was de-
signed to investigate the effect of this in-
tervention on glycemic control in poorly
controlled, insulin-naïve type 2 diabetic
patients compared with enhanced usual
care. Additionally, we assessed the effect
of this intervention on SMBG frequency,
timing and intensity of treatment modiﬁ-
cation, and general well-being (GWB).
RESEARCH DESIGN AND
METHODS—The Structured Testing
Program (STeP) is a 12-month, cluster-
randomized, multicenter comparison be-
tween poorly controlled (A1C $7.5%),
noninsulin-treated type 2 diabetic patients
using structured SMBG in conjunction
with enhanced usual care (structured
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ORIGINAL ARTICLEtesting group [STG]) and an active control
group (ACG) that received enhanced
usual care only. Enhanced usual care in-
cluded quarterly clinic visits that focused
speciﬁcally on diabetes management, free
bloodglucosemetersandstrips,andofﬁce
point-of-care A1C capability.
Patients were recruited from primary
care practice sites across the eastern U.S.,
whichwerestratiﬁedtoSTGorACG.This
included both small and large practices
serving communities with a range of
patient education, social class, and eth-
nicity that reﬂected the diversity of pri-
mary care settings in the U.S. The use of a
stratiﬁed, cluster-randomized design en-
sured that physicians cared for patients
from one study group only. Each site
generated a list of all patients who met
age, diagnosis, and A1C inclusion criteria
from their patient databases or chart re-
view. Participating physicians reviewed
the list and eliminated patients whom
they felt should not participate in the
study (e.g., dementia, psychosis, recent
emotional trauma). Patients were then
randomly selected from the list using a
study-deﬁn e dp r o t o c o lu n t i lt h ep r e d e -
termined sample size was reached.
Inclusion criteria were: duration of
type 2 diabetes .1y e a r ;a g e d$25 years;
A1C level 7.5–12.0%; currently treated by
diet, exercise, oral diabetes medication,
and/or injectable incretin mimetic; able to
read and write English without assistance;
and had not participated in any other re-
searchprotocolwithinthelast30days.Ex-
clusion criteria were: type 1 diabetes;
managed with insulin at the start of the
study; C-peptide level #0.50 ng/mL;
used systemic oral or inhaled steroids
more than 14 days within the last 3
months; treated with chemotherapy or
radiation therapy; pregnant or breast-
feeding; or had severe depression or other
severe psychological conditions.
The study protocol was approved by
the Copernicus Group (Central Institu-
tionalReviewBoard)andisincompliance
with the Helsinki Declaration (15). Writ-
ten informed consent was obtained from
all subjects.
Procedures
The study’s duration was 12 months with
patient visits occurring at initial screening
and baseline followed by visits at months
1, 3, 6, 9, and 12. At screening, investiga-
tors recorded demographics, collected rel-
evant medical history, performed physical
examinations,collectedlaboratorysamples
(e.g., A1C, lipids), and documented all
current medications. Patients completed
the STeP questionnaire, which included
measures of self-care, diabetes-related dis-
tress, depression, and GWB. A description
ofthesemeasureswaspreviouslypublished
(14). A baseline visit was scheduled within
14 days. At the baseline visit, laboratory
results were reviewed. Patients in both
arms received a free blood glucose meter
and test strips (Accu-Chek Aviva meter
system; Roche Diagnostics, Indianapolis,
IN), and they were instructed in their use.
At all subsequent visits (months 1, 3,
6, 9, and 12), ACG and STG clinic staff
collected laboratory samples, recorded
changes in medications, and performed
briefphysicalexaminations.Point-of-care
A1Cequipment(A1CNow+testkit;Bayer
Healthcare,Tarrytown,NY)wasprovided
to all practices for clinical use only to
assure that differential availability of the
equipment did not affect outcomes. Pa-
tientsinbothgroupsbroughttheirmeters
to each subsequent visit for electronic
datauploading;physiciansandclinicstaff
were blinded to these data and all other
study-collected measures. Patients also
reported all changes made to their di-
abetes regimen since their last visit. All
patients completed the STeP question-
naire and a post-visit questionnaire to
record physician discussion of SMBG
results and recommendations for phar-
macologic and lifestyle changes that oc-
curred during the visit.
Intervention
STG participants used the Accu-Chek
360° View blood glucose analysis system
(Roche Diagnostics), a validated tool (16)
that enabled patients to record/plot a 7-
point SMBG proﬁle (fasting, preprandial/
2 - hp o s t p r a n d i a la te a c hm e a l ,b e d t i m e )
on3consecutivedayspriortoeachsched-
uled study visit (months 1, 3, 6, 9, and
12), to document meal sizes and energy
levels, and to comment on their SMBG
experiences. STG participants received
training in the use of the Accu-Chek sys-
tem, including instructions for how to
identify problematic glycemic patterns
and how best to address such problems
through changes in physical activity, por-
tion sizes, and/or meal composition. STG
patients and physicians reviewed the
completed form at each of the scheduled
visits and noted areas of needed medica-
tion and lifestyle change. Completion of
the Accu-Chek system was prompted
via a telephone call from their physician’s
ofﬁce one week prior to their next ap-
pointment. ACG subjects did not receive
the Accu-Chek system. ACG patients
were instructed to use their meter follow-
ing their physicians’ recommendations
but received no additional SMBG
prompting, training, or instruction.
STG physicians/staff received training
on interpreting the structured data and
were provided with an algorithm that de-
scribed various pharmacologic/lifestyle
treatment strategies that could be used
in response to the speciﬁcS M B Gp a t -
terns identiﬁed. Physicians were free to
select from these options based on patient/
physician preferences. All STG physicians
were contacted regularly over the 12
months of the study to ensure consistency
oftheinterventionovertime.ACGphysi-
cians and staff received no additional
training. STeP Study tools and resources
are available at www.behavioraldiabetes.
org/studies/STeP-Study.html.
Measurements
TheprimaryendpointwaschangeinA1C
from screening to 12 months. A1C anal-
ysiswasconductedbyacentrallaboratory
(Covance, Indianapolis, IN) using the
Variant II and Variant II Turbo hemoglo-
bin testing systems (Bio-Rad Laborato-
ries, Hercules, CA).
Treatment intensiﬁcation was calcu-
lated using information entered into pa-
tient medical records at each clinic visit.
These included recommended pharmaco-
logicmodiﬁcation(deﬁnedastheinitiation
ofanewmedication,increaseordecreasein
the dose of an existing medication, or
termination of an existing medication)
and recommended lifestyle modiﬁcation
(deﬁned as any change in diet, exercise, or
otherself-carebehavior).Thetotalnumber
of visits with medication or lifestyle mod-
iﬁcat ionsandthetimetotheﬁrsttreatment
change was recorded for all patients.
FrequencyofSMBGforallpatientswas
calculated from blood glucose meter data
that were uploaded electronically by the
site coordinator directly to a web server at
each study visit via the Accu-Chek Smart
Pix device (Roche Diagnostics).
GWBwasmeasuredusingtheWHO-5
Well-Being Index assessment tool (17), a
widelyused,ﬁve-itemquestionnairewitha
total score range of from 0–100 (higher
scoresindicatingmorepositivewell-being).
Findings regarding other patient-reported
outcomes will be presented in subsequent
reports.
Statistical analysis
T h es t u d yw a sd e s i g n e dt oh a v ea9 0 %
power to detect a difference of 0.5% in
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two-sample t test (two-sided, a = 0.05),
assuming a common SD of 1.5%. The es-
timate of SD in A1C values was inﬂated
from 1.15 to 1.50 because of the cluster-
ing effect (18,19). We required a total of
408 patients (204 per study arm) to ach-
ieve the speciﬁed statistical power. A
larger STG sample was initially recruited
to account for potentially greater attrition
expected in this group over time.
The analysis of change in A1C and
other dependent variables was performed
using linear mixed models (LMM) analy-
siswithSASPROCMIXED(20,21).LMM
allows for comparisons between groups
across study waves over time, along with
analyses of moderator and mediator vari-
ables within the same analytic frame
(20,21). Control variables in all analyses
included: baseline dependent variable
(A1C); patient age, gender, and race
(white/nonwhite) as ﬁxed effects; and
practice site and subject as random ef-
fects. Missing data were estimated using
maximum likelihood methods (22).
B a s e do nt h em i x e dm o d e l ,t h el e a s t -
square estimates of the group differences
were obtained and tested for statistical
signiﬁcance. Additional analyses of pa-
tient attrition at each step in the protocol
also were undertaken.
LMM was performed in two ways
using values from all study visits across
the 12 months. In the ﬁrst approach, the
analysis focused on the intent-to-treat
(ITT) population, which was deﬁned as
ACG and STG subjects who completed
the baseline and at least one postbaseline
visit. The second approach was a per
protocol (PP) analysis, which included
allACGandSTGpatientswhoadhered to
thestudyprotocol.AdherenceintheACG
was deﬁned as those who completed the
study (with $4 visits) and did not use
structured SMBG records that were simi-
lar to the Accu-Chek 360° View blood
glucose analysis system intervention
tool. Adherence in the STG was deﬁned
asthosewhocompletedatleast80%ofall
blood glucose values on the intervention
tool, brought their completed tool to the
clinic visit, and reported that their physi-
cians looked at the tool and discussed the
results (via the Post-Visit Questionnaire)
at $4 of the 5 clinic visits.
RESULTS—We recruited 34 primary
care practices that were then randomized
withstratiﬁcation toACG (n =13)orSTG
(n = 21) (Fig. 1). Of the 770 patients
screened, 499 patients were eligible and
enrolled in the study. Of these, 7 patients
(ACG, n =1 ;S T G ,n = 6) withdrew con-
sent, and 9 patients (ACG, n =2 ;S T G ,n =
7) were lost to follow-up. The remaining
483patients(ACG,n=227;STG,n=256)
were included in the ITT cohort. During
the study, 15 patients discontinued, 24
withdrew consent, and 69 were lost to
follow-up, all primarily because of time
or other life demands. Dropouts were
slightly younger (P , 0.02), more likely
to be African American (P , 0.02), had a
higher A1C (P , 0.01), and had fewer
comorbid conditions at baseline (P ,
0.02). Characteristics of the dropouts
were not signiﬁcantly different between
the two study groups. An additional 84
patients (ACG, n = 26; STG, n = 58)
were excluded from the PP analyses be-
cause of protocol nonadherence. Thus,
the PP cohort included 161 (71%) ACG
patients and 130 (51%) STG patients.
Site and patient characteristics are
summarized in Table 1. Patient demo-
graphic and disease-related characteris-
tics at baseline between the two study
groupsdifferedonlybyageandethnicity.
These differences were controlled in
all subsequent analyses. There were no
intervention-related adverse events.
Over the 12 months, no severe hypoglyce-
mic events were reported. The incidence
of hypoglycemia (,70 mg/dL), based on
downloaded meter data, was 1.9% in the
ACGand 1.8% inthe STG (P=NS).There
were no signiﬁcant differences between
thegroupsinnumberoftotalvisits(sched-
uled study visits plus follow-up visits) over
the12months(ACG=5.1[2.2];STG=4.9
[2.6], P =0 . 5 6 )
A1C ﬁndings
ITT analysis revealed that both groups
showed signiﬁcant reductions in A1C
levels; however, STG subjects evidenced
signiﬁcantlygreatermean(SE)reductions
in A1C than ACG subjects over the 12
months:21.2%(0.09)vs.20.9%(0.10);
D=20.3%;P=0.04(Fig.2A).PPanalysis
revealed an even greater mean (SE) A1C
reductionamongthose STGsubjects who
adhered to the intervention compared
with ACG subjects: 21.3% (0.11) vs.
20.8% (0.11); D = 20.5%; P , 0.003
(Fig. 2B). It is noteworthy that A1C re-
ductions in nonadherent STG subjects
were not signiﬁcantly different than re-
ductions seen in ACG subjects.
Seven-point blood glucose proﬁle
ﬁndings
STG subjects showed signiﬁcantly lower
averagepreprandialandpostprandialglu-
cose levels at all meals and at bedtime
from month 1 to month 12 (in all cases,
P , 0.001). More importantly, there was a
signiﬁcantdropfrommonth1tomonth12
in preprandial to postprandial glucose
excursions at all meals: breakfast (44 to
35 mg/dL, P , 0.005), lunch (25 mg/dL
Figure 1—Consort diagram.
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to26mg/dL,P,0.05).Measurementsof
meanamplitudeofglucoseexcursionsin-
dicated signiﬁcant (P = 0.0003) mean
(SE) reductions in glycemic variability
among STG subjects from 38.5 mg/dL
( 0 . 9 )a tm o n t h1t o3 4 . 3m g / d L( 1 . 0 )a t
month 12. There were no changes in
these ﬁndings when insulin-using pa-
tients were excluded from the analyses.
Changes in treatment
ITT analysis showed that patients in both
study groups who received a treatment
changerecommendation(pharmacologic
and/or lifestyle) at the month 1 visit expe-
rienced signiﬁcantly (P , 0.0005) greater
reductions in A1C than patients who did
not receive a treatment change recom-
mendationatthemonth1visit.However,
signiﬁcantly more STG patients received a
treatment change recommendation at the
month1visitcomparedwithACGpatients,
regardless of the patient’sb a s e l i n eA 1 C
level: 179 (75.5%) vs. 61 (28.0%); P ,
0.0001. Of note, almost twice as many
STG patients were started on intermediate
or long-acting insulin than ACG patients
betweenthemonth1andmonth12visits:
42 vs. 23; P = 0.046. ITT analyses exclud-
ing patients who began insulin during the
study period also indicated signiﬁcant de-
creases in A1C for both the ACG and the
STG, with STG patients still demonstrat-
ingsigniﬁcantlygreaterreductionsinA1C
by month 12 than ACG patients: 21.3%
(0.10) vs. 21.0% (0.10); D = 20.3%; P =
0.03. Similar between-group differences
occurred using last observation carried
forward analysis (last A1C before insulin
start carried forward): 21.0% (0.10) vs.
20.7% (0.10); D = 20.3%; P = 0.03.
Thus, the observed group difference in
glycemic outcomes was not accounted
for by those patients who started insulin
during the course of the study.
The mean (SD) number of scheduled
visits at which a treatment change was
recommended was signiﬁcantly higher in
STG patients than in ACG patients: 2.7
(1.5) vs. 1.1 (1.0); P , 0.0001. PP analy-
ses showed that the mean (SD) number
of clinic visits where treatment change
recommendations occurred was almost
three times greater in STG patients than
in ACG patients: 3.1 (1.4) vs. 1.1 (1.0),
P , 0.0001.
SMBG frequency
ITT analyses showed that the mean (SD)
number of daily blood glucose tests, even
when including the 7-point Accu-Chek
360° View blood glucose analysis system
proﬁles for the STG, was signiﬁcantly
lower for the STG than for the ACG at
month 6 (0.97 [0.81] vs. 1.21 [1.00],
P = 0.007); month 9 (0.85 [0.72] vs. 1.11
[0.84], P = 0.001); and month 12 (0.77
[0.69] vs. 1.05 [0.80], P , 0.0001). PP
analysis showed no signiﬁcant between-
group differences in SMBG frequency.
General well-being
There was a signiﬁcant increase in GWB
over the study period in both the ACG
(P,0.007)andtheSTG(P,0.0001),as
assessed by the WHO-5 (16), with no sig-
niﬁcant between-group differences over
time. In the ACG, mean (SD) WHO-5
scores rose from 58.0 (20.7) at study start
to 62.0 (20.8) at month 12. In the STG,
mean (SD) WHO-5 scores rose from 57.3
(23.6) at study start to 65.5 (21.3) at
month 12. PP analyses revealed that ad-
herent STG subjects reported a signiﬁ-
cantly greater improvement in GWB
than adherent ACG subjects (P , 0.04).
CONCLUSIONS—We found that
programmatic, structured SMBG contrib-
utes to signiﬁcant improvement in glyce-
mic control in insulin-naïve type 2
diabetic patients compared with patients
who did not receive structured SMBG.
Further, this signiﬁcant between-group
difference occurs even though there is a
signiﬁcant A1C reduction of 0.9% ach-
ieved by the ACG during the 12-month
studyperiod.Glycemicimprovementwas
even greater inSTGpatients whoadhered
to the protocol. Of note, patients in the
structured SMBG group also show im-
provement in mean amplitude of glucose
excursions and in 7-point blood glucose
proﬁles over the 12-month period.
We suspect that the signiﬁcant A1C
improvementintheACGovertimeisdue
mainlytotheheightenedattentionpaidto
Table 1—Baseline characteristics of practice sites and patients with type 2 diabetes by
randomization group
Practice sites All sites ACG STG P
n 34 13 21
Physician age: mean (SD) age (years) 44.8 (7.7) 43.3 (6.4) 45.7 (8.4) 0.3867
Gender: male 27 (79.4) 11 (84.6) 16 (76.2) 0.5549
Years in practice: mean (SD) (years) 13.1 (7.9) 11.3 (7.2) 14.1 (8.3) 0.3441
Type of practice 0.4289
Primary care 27 (79.5) 10 (76.9) 17 (81.0)
Multispecialty care 6 (17.6) 2 (15.4) 4 (19.0)
Primary care/multispecialty care 1 (2.9) 1 (7.7) 0 (0.0)
Number of type 2 diabetic patients:
mean (SD) 1,084 (1,483) 1,250 (2,023) 978 (1,065) 0.6276
Primary location of practice 0.3024
Rural setting 10 (29.4) 2 (15.4) 8 (38.1)
Suburban 17 (50.0) 9 (69.2) 8 (38.1)
Urban 6 (17.6) 2 (15.4) 4 (19.0)
Urban and suburban 1 (3.0) 0 (0.0) 1 (4.8)
Patients All patients ACG STG P
n 483 227 256
Patient age: mean (SD) age (years) 55.8 (10.7) 57.0 (11.2) 54.8 (10.1) 0.0197
Gender: male 257 (53.2) 122 (53.7) 135 (52.7) 0.8243
Ethnicity 0.0004
African American 150 (31.1) 72 (31.7) 78 (30.5)
Caucasian 305 (63.1) 152 (67.0) 153 (59.8)
Other 28 (5.8) 3 (1.3) 25 (9.8)
Highest level of education 0.1002
No college 253 (52.7) 114 (50.9) 139 (54.3)
Some college 98 (20.4) 40 (17.9) 58 (22.7)
College graduate 129 (26.9) 70 (31.3) 59 (23.0)
A1C: mean (SD) A1C (%) 8.9 (1.2) 8.9 (1.2) 8.9 (1.2) 0.8751
BMI: mean (SD) BMI (kg/m
2) 35.1 (7.3) 35.1 (6.7) 35.0 (7.8) 0.8851
Diabetes duration: mean (SD) (years) 7.6 (6.1) 7.7 (6.1) 7.5 (6.1) 0.6547
Values are n (percentages) unless stated otherwise.
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strips,therequirementthatsubjectsbring
their meters to all study visits, and the
more frequent than usual medical visits.
Thus, the observed differences between
the STG and the ACG may be a conser-
vative estimate compared with what
might be obtained with similar patients
in most clinical settings.
We also found signiﬁcant differences
between the STG and the ACG in the
frequency and intensity of the treatment
change recommendations made by physi-
cians. This suggests that when patients
bring structured SMBG information to
clinic visits, and when physicians know
how to interpret and respond to SMBG
information, timely and appropriate
treatment changes are more likely to
occur than in cases in which structured
SMBG data are not available, as occurred
in the ACG.
Another possible explanation is that
the treatment changes made by the STG
physicians, and the resulting improve-
ments in A1C, occurred because only the
STG physicians were trained on a treat-
ment algorithm and were encouraged to
follow it. However the PP analyses show
that the glycemic advantage occurred
only among the STG patients who ad-
heredtotheintervention.Therefore,phy-
sician training alone does not sufﬁciently
explain these ﬁndings.
Additionally, the greater improve-
ment in A1C over time in the STG than
in the ACG occurred with less (ITT)
SMBG frequency. This ﬁnding has im-
portant policy implications, suggesting
that it may be appropriate to shift the
current focus from SMBG quantity (test-
ing frequency) to SMBG quality (mean-
ingful test results that contribute to
positive action), utilizing protocols that
place more emphasis on when patients
test and how they and their physicians
organize and make clinically relevant use
of the resulting data.
Study strengths and weaknesses
We used a comprehensive approach to
address the design limitations of previous
studies (23): a cluster-randomized de-
sign; an A1C inclusion criterion of
$7.5%; a highly structured protocol
that led to actionable outcomes for both
patients and physicians; and a set of PP
analyses to determine the effects of pro-
tocol completion.
Several limitations are noteworthy.
First, the study did not include a third
study arm that would have assessed the
effect of the increased attention paid to
both study groups over the 12-month
period. Thus, the enhanced usual care
received by the ACG resulted in a conser-
vative estimate of between-group differ-
ences. Second, we could not determine if
the treatment changes initiated by the
physiciansandthepatientswereclinically
appropriate; our measures examined the
number of changes, rather than the type
ofchangerecommended.Third,wecould
not determine how many of the recom-
mended treatment changes actually oc-
curred. Fourth, there was more attrition
ofthe STGpatientsthan theACG patients
over the 12-month period (though this
difference was not statistically signiﬁ-
cant), suggesting that some patients may
have found the structured SMBG inter-
ventiontooburdensome,whichmayhave
biased the ﬁndings.
Ourﬁndingsdemonstratethatappro-
priate use of SMBG in poorly controlled,
insulin-naïve type 2 diabetic patients can
Figure 2—A: ITT analysis: mean (6 SE) A1C over 12 months (M) in patients with noninsulin-
treatedtype2diabetesaccording torandomizationgroup.B:PP analysis:mean(6SE)A1Cover
12 months (M) in patients with noninsulin-treated type 2 diabetes, comparing ACG patients,
adherent STG (STG/a) patients, and nonadherent STG (STG/na) patients.
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This suggests that most patients and
physicians will make appropriate use of
SMBG data when there is a well-deﬁned
testing protocol, a tool for organizing the
data, and the knowledge to interpret the
data. It is evident that physicians can be
trained to use well-organized SMBG data
and to collaborate with patients to make
timely and effective treatment decisions to
improve glycemic control. Integrating
SMBG into a collaborative program of
care may lead to improved glycemic con-
trol without increasing strip consumption.
Acknowledgments—Funding for the study
was provided by Roche Diagnostics, India-
napolis, Indiana. W.H.P., D.A.H., and C.G.P.
have worked as consultants for Roche Diag-
nosticsandAbbottDiabetesCare.L.F.,C.H.S.,
and Z.J. have worked as consultants for Roche
Diagnostics. B.P., M.S., and R.S.W. are em-
ployed by Roche Diagnostics. No other po-
tential conﬂicts of interest relevant to this
article were reported.
The study conception/protocol was by
W.H.P., L.F., M.S., and R.S.W. Subject train-
ing was by D.A.H., C.H.S., and C.G.P. The
clinicaloperationsstudymanagerwasB.P.The
statistical analysis was by Z.J. The manuscript
development was by W.H.P., L.F., and C.G.P.
The manuscript was reviewed by an indepen-
dent Publication and Analysis Committee,
which had full and independent access to all
study data and independent responsibility for
the development, writing, and oversight of all
manuscripts. The committee is comprised of
W.H.P.; L.F.; M.S.; R.S.W.; Richard Bergenstal,
MD; Frank Snoek, PhD; and David Owens,
MD. All authors read and approved the ﬁnal
manuscript.
Parts of this study were presented in poster
form at the 70th ScientiﬁcS e s s i o n so ft h e
American Diabetes Association (ADA), Or-
lando, Florida, 25–29 June 2010; the 45th
Annual Meeting of the European Association
for the Study of Diabetes, Vienna, Austria, 29
September–2 October 2009; and the 69th
Scientiﬁc Sessions of the ADA, New Orleans,
Louisiana, 5–9J u n e2 0 0 9 .
The authors thank the participating clini-
cians and patients for their assistance and
commitment to this research effort.
References
1. AmericanDiabetesAssociation.Standards
of medical care in diabetes–2010. Di-
abetes Care 2009;32(Suppl. 1):S4–S10
2. Rodbard HW, Blonde L, Braithwaite SS,
et al; AACE Diabetes Mellitus Clinical
Practice Guidelines Task Force. American
Association of Clinical Endocrinologists
medical guidelines for clinical practice for
the management of diabetes mellitus.
Endocr Pract 2007;13(Suppl. 1):1–68
3. IDF Clinical Guidelines Task Force.
Global guideline for type 2 diabetes. In-
ternational Diabetes Federation 2005.
Available from www.idf.org. Accessed 10
April 2010
4. The Diabetes Control and Complications
Trial Research Group. The effect of in-
tensive treatment of diabetes on the de-
velopment and progression of long-term
complications in insulin-dependent di-
abetes mellitus. N Engl J Med 1993;329:
977–986
5. Evans JM, Newton RW, Ruta DA,
MacDonaldTM,StevensonRJ,MorrisAD.
Frequencyofbloodglucosemonitoringin
relation to glycaemic control: observa-
tional study with diabetes database. BMJ
1999;319:83–86
6. Nathan DM, McKitrick C, Larkin M,
Schaffran R, Singer DE. Glycemic control
in diabetes mellitus: have changes in
therapy made a difference? Am J Med
1996;100:157–163
7. Karter AJ, Ackerson LM, Darbinian JA,
et al. Self-monitoring of blood glucose
levels and glycemic control: the Northern
California Kaiser Permanente Diabetes
registry. Am J Med 2001;111:1–9
8. Guerci B, Drouin P, Grangé V, et al; ASIA
Group. Self-monitoring of blood glucose
signiﬁcantly improves metabolic control
in patients with type 2 diabetes mellitus:
the Auto-Surveillance Intervention Active
(ASIA) study. Diabetes Metab 2003;29:
587–594
9. SchwedesU,SieboldsM,MertesG;SMBG
Study Group. Meal-related structured
self-monitoringofbloodglucose:effecton
diabetes control in non-insulin-treated
type 2 diabetic patients. Diabetes Care
2002;25:1928–1932
10. Barnett AH, Krentz AJ, Strojek K, et al.
The efﬁcacy of self-monitoring of blood
glucose in the management of patients
with type 2 diabetes treated with a gli-
clazidemodiﬁedrelease-basedregimen.A
multicentre, randomized, parallel-group,
6-month evaluation (DINAMIC 1 study).
DiabetesObesMetab2008;10:1239–1247
11. FarmerA,WadeA,GoyderE,etal.Impact
of self monitoring of blood glucose in the
management of patients with non-insulin
treated diabetes: open parallel group
randomised trial. BMJ 2007;335:132
12. O’Kane MJ, Bunting B, Copeland M,
Coates VE; ESMON study group. Efﬁcacy
of self monitoring of blood glucose in
patients with newly diagnosed type 2
diabetes(ESMONstudy):randomisedcon-
trolled trial. BMJ 2008;336:1174–1177
13. Davidson MB, Castellanos M, Kain D,
Duran P. The effect of self monitoring of
blood glucose concentrations on glycated
hemoglobin levels in diabetic patients not
taking insulin: a blinded, randomized
trial. Am J Med 2005;118:422–425
14. Polonsky W, Fisher L, Schikman C, et al.
The value of episodic, intensive blood
glucose monitoring in non-insulin treated
persons with type 2 diabetes: design of
the Structured Testing Program (STeP)
study, a cluster-randomised, clinical trial
[NCT00674986]. BMC Fam Pract 2010;
11:37
15. World Medical Association Declaration
of Helsinki. Recommendations guiding
physiciansinbiomedicalresearchinvolving
humansubjects. JAMA 1997;277:925–926
16. Polonsky WH, Jelsovsky Z, Panzera S,
Parkin CG, Wagner RS. Primary care
physicians identify and act upon glycemic
abnormalities found in structured, epi-
sodic blood glucose monitoring data from
non-insulin-treated type 2 diabetes. Di-
abetes Technol Ther 2009;11:283–291
17. Bech P, Olsen LR, Kjoller M, Rasmussen
NK. Measuring well-being rather than the
absence of distress symptoms: a compari-
son of the SF-36 Mental Health subscale
and theWHO-Five Well-Being Scale.Int J
Methods Psychiatr Res 2003;12:85–91
18. Littenberg B, MacLean CD. Intra-cluster
correlation coefﬁcients in adults with di-
abetes in primary care practices: the Ver-
mont Diabetes Information System ﬁeld
survey. BMC Med Res Methodol 2006;6:20
19. Kinmonth AL, Woodcock A, GrifﬁnS ,
Spiegal N, Campbell MJ; The Diabetes
Care From Diagnosis Research Team.
Randomised controlled trial of patient
centred care of diabetes in general practice:
impact on current wellbeing and future
disease risk. BMJ 1998;317:1202–1208
20. SAS Institute. SAS/STAT User’sG u i d e .
8 ed. Cary, NC, SAS Institute, Inc., 1999
21. Fitzmaurice G, Laird NM, Ware JH. Ap-
plied Longitudinal Analysis. Hoboken, NJ,
John W. Wiley and Sons, 2004
22. Little RJA, Rubin DB. Statistical Analysis
with Missing Data. 2nd ed. Hoboken, NJ,
John W. Wiley and Sons, 2002
23. Klonoff DC, Bergenstal R, Blonde LS, et al.
Consensus report ofthe coalition for clinical
research-self-monitoring of blood glucose.
J Diabetes Sci Tech 2008;2:1030–1053
care.diabetesjournals.org DIABETES CARE, VOLUME 34, FEBRUARY 2011 267
Polonsky and Associates